Citations

Clear

12 citation(s) found for "Sukumar, S".

Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer
Fackler, Mary Jo , Lopez‐Bujanda, Zoila A. , Umbricht, Christopher B. , Teo, Wei Wen , Cho, Soonweng , Zhang, Zhe , Visvanathan, Kala , Jeter, Stacie C., Argani, Pedram, Lyman, Jaclyn P. , Brot, Marina De , McGuire, Kandace P. , King, Tari A. , Cope, Leslie , Wolff, Antonio C. , Wang, Chenguang , Ingle, James N. , Boughey, Judy C. , Carey, Lisa A. , Sukumar, Saraswati , Wolff, Antonio C , Visvanathan, Kala , Lopez-Bujanda, Zoila A

Mayo Clinic

Cancer Research | April 15, 2014 | Volume: 74 | Issue: 8 | Pages: 2160-2170

10.1158/0008-5472.can-13-3392 | PMID 24737128 Get It

Abstract The ability to consistently detect cell-free tumor-specific DNA in peripheral blood of patients with metastatic breast cancer provides the opportunity to detect changes in tumor burden and to monitor response to treatment. We developed cMethDNA, a quantitative multiplexed methylation-specific PCR assay for a panel of ten genes, consisting of novel and known breast cancer hypermethylated markers identified by mining our previously reported study of DNA methylation patterns in breast tissue (103 cancer, 21 normal on the Illumina HumanMethylation27 Beadchip) and then validating the 10-gene panel in The Cancer Genome Atlas project breast cancer methylome database. For cMethDNA, a fixed physiologic level (50 copies) of artificially constructed, standard nonhuman reference DNA specific for each gene is introduced in a constant volume of serum (300 μL) before purification of the DNA, facilitating a sensitive, specific, robust, and quantitative assay of tumor DNA, with broad dynamic range. Cancer-specific methylated DNA was detected in training (28 normal, 24 cancer) and test (27 normal, 33 cancer) sets of recurrent stage IV patient sera with a sensitivity of 91% and a specificity of 96% in the test set. In a pilot study, cMethDNA assay faithfully reflected patient response to chemotherapy (N = 29). A core methylation signature present in the primary breast cancer was retained in serum and metastatic tissues collected at autopsy two to 11 years after diagnosis of the disease. Together, our data suggest that the cMethDNA assay can detect advanced breast cancer, and monitor tumor burden and treatment response in women with metastatic breast cancer. Cancer Res; 74(8); 2160–70. ©2014 AACR.
Health care‐associated infections after major cancer surgery
Sammon, Jesse D. , Trinh, Vincent Quoc‐Huy , Ravi, Praful , Sukumar, Shyam, Gervais, Mai‐Kim , Larouche, Alexandre , Kim, Simon P. , Menon, Mani, Karakiewicz, Pierre I. , Sun, Maxine , Shariat, Shahrokh F. , Tian, Zhe Wen , Kowalczyk, Keith J. , Hu, Jim C. , Trinh, Quoc‐Dien

Mayo Clinic

Cancer | March 19, 2013 | Volume: 119 | Issue: 12 | Pages: 2317-2324

10.1002/cncr.28027 | PMID 23512473 Get It

BACKGROUNDApproximately 1.7 million individuals per year are affected with health care‐associated infections (HAIs) in the United States. The authors examined trends in the incidence of HAI after major cancer surgery (MCS) and risk factors for HAI to describe the effects of HAI on mortality after MCS.METHODSPatients undergoing 1 of 8 MCS procedures within the Nationwide Inpatient Sample between 1999 and 2009 were identified (n = 2,502,686). Generalized linear regression models were used to estimate the impact of the primary predictors (procedure type, age, sex, race, insurance status, Charlson comorbidity index, hospital volume, and hospital bed size) on the odds of HAI and in‐hospital mortality. Trends in incidence were evaluated with linear regression.RESULTSOverall, MCS‐associated HAI incidence increased 2.7% per year (P < .001), whereas mortality decreased 1.3% per year (P < .001). Male gender (odds ratio [OR], 1.12, 95% confidence interval [CI], 1.10‐1.14), advancing age (OR, 1.02; 95% CI, 1.02‐1.02), black race (OR, 1.26; 95% CI, 1.21‐1.31), ≥1 comorbidities (OR, from 1.08 [95% CI, 1.04‐1.13] to 1.31 [95% CI, 1.27‐1.35]), and nonprivate insurance (OR, from 1.18 [95% CI, 1.15‐1.22] to 1.67 [95% CI, 1.59‐1.76]) were associated with an increased odds of HAI on multivariable analysis. Conversely, increasing hospital volume was associated with lower odds of HAI (OR, 0.999; 95% CI, 0.99‐0.99). Patients with MCS‐associated HAI had increased odds of mortality (OR, 8.66; 95% CI, 8.51‐8.82).CONCLUSIONSBetween 1999 and 2009, the incidence of MCS‐associated HAI events increased; however, HAI‐associated mortality decreased. That said, significant disparities exist in the hospital and demographic attributes associated with MCS‐associated HAI, with attendant health policy implications. Moreover, HAI remains detrimentally linked to mortality during hospitalization. Cancer 2013;119:2317–2324. © 2013 American Cancer Society.